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ABSTRACT
Objectives: To construct and validate a prediction model of
preference-adjusted health status (EQ-5D) for metastatic
hormone-refractory prostate cancer (HRPCA) patients using
cancer-speciﬁc health-related quality of life (HRQoL)
measures.
Methods: Data were obtained from a multicenter, multina-
tional observational study of metastatic HRPCA patients
conducted during 2002 to 2004. In addition to clinical
and resource utilization, preference-adjusted health status
(EQ-5D) and HRQoL (Functional Assessment of Cancer
Therapy—Prostate [FACT-P] and European Organization for
Research and Treatment of Cancer Quality of Life Question-
naire [EORTC QLQ-C30]) data were collected. Predictive
validity of ordinary least square (OLS) and median regres-
sions of various model speciﬁcations were tested using cross-
validation samples. The selected speciﬁcation was then
further reﬁned and tested for alternative model speciﬁcations
and restrictions.
Results: OLS regression with both HRQoL measures as
individual components and patient demographics was the
best-performing model. It explained 58.2% of the observed
EQ-5D variation in the validation sample. A model including
only the prostate cancer-speciﬁc HRQoL measure, FACT-P,
explained 53.5% of the observed EQ-5D variation.
Conclusions: The models developed have good predictive
validity. These algorithms enable researchers to translate
cancer-speciﬁc HRQoL measures to preference-adjusted
health status in metastatic HRPCA patients. The ﬁndings
will help perform health status adjustments in cost-utility
analyses.
Keywords: EORTC QLQ-C30, EQ-5D, FACT-P, preference-
adjusted health status, quality of life.
Introduction
Prostate cancer is a common disease among men in
many Western countries. After the age of 40 years, the
prevalence of prostate cancer increases signiﬁcantly,
up to 80% by the age of 80 years [1]. Currently, there
are approximately 1.9 million patients with prostate
cancer in the United States [2]. Although most pros-
tate cancer patients initially respond to hormone-
ablation treatment, many go on to develop metastatic
hormone-refractory prostate cancer (HRPCA), which
eventually causes patient death [3,4]. Each year,
approximately 30,000 patients die of HRPCA [5].
Metastatic HRPCA is a disease associated with debili-
tating symptoms, speciﬁcally severe bone pain,
reduced life expectancy, and no possibility of cure. In
this setting, the focus is usually on palliative therapies
that provide symptom relief. Multidimensional
health-related quality of life (HRQoL) measures, such
as the Functional Assessment of Cancere Therapy—
Prostate (FACT-P) and the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30), provide patients
with tools to subjectively evaluate their own health
status. Nevertheless, these HRQoL tools do not
provide information on preference-adjusted health
status. This can be captured using tools such as the
EuroQoL 5D (EQ-5D). The preference-adjusted
health status measures are crucial to developing the
cost-utility models used in appraising health-care
technologies.
HRPCA trials routinely collect HRQoL informa-
tion. Nevertheless, preference-adjusted health status
data such as EQ-5D values are rarely collected, prima-
rily because of the concerns of patient burden. When
patient health status information is not collected,
models are needed that can reasonably predict health
utilities based on the HRQoL data to study the cost-
utility of interventions. Previous research resulted in
the creation of health utility measures, in particular the
HUI, derived from the Short-Form-36 (SF-36) ques-
tionnaire and its abbreviated form, the SF-12 [6–9].
Others have also derived mapping from SF-12 to
EQ-5D [9,10]. Such models, which map HRQoL to
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health utilities, do not exist for the metastatic HRPCA
population. Therefore, the objective of this study is
to derive a prediction model of metastatic HRPCA
patient preference-adjusted health status measured
with EQ-5D using patient demographics and patient
HRQoL measured by two cancer-speciﬁc HRQoL
questionnaires: the FACT-P and the EORTC QLQ-
C30. The development and test of the model used data
from a multinational HRPCA prospective observa-
tional study.
EQ-5D is a standardized instrument used to
measure preference-adjusted health status; it is cogni-
tively simple and takes only a few minutes to complete.
It is applicable to a wide range of health conditions
and treatments and provides a simple descriptive
proﬁle and a single index value for health status. It is
designed to be completed by the respondents them-
selves and is ideally suited for use in postal surveys, in
clinics, and in face-to-face interviews. Recently, EQ-5D
preference weights speciﬁc to the United States have
been developed [11]. Nevertheless, a majority of the
literature on the EQ-5D have used UK preference
weights. To keep results consistent across study centers
in different countries, and comparable to previous
research, we applied the UK preference weights in this
analysis.
FACT-P comprises the Functional Assessment of
Cancer Therapy—General (FACT-G) and a prostate
cancer subscale [12]. The FACT-G includes 29 items
that measure HRQoL in cancer patients and is com-
pleted by the patients themselves. It consists of ﬁve
subscales measuring physical, functional, social/family,
and emotional well-being and satisfaction with the
doctor–patient relationship. The FACT-G can be self-
administered or used in an interview format. The pros-
tate cancer subscale of the FACT-P includes 12 items
speciﬁcally designed to measure the HRQoL in pros-
tate cancer patients. The FACT-P is scored by summing
the ﬁve subscales of the FACT-G plus the prostate
cancer subscale to yield a comprehensive HRQoL
score [13].
The EORTC QLQ-C30 includes 30 items and is
composed of scales that evaluate functioning, symp-
toms, and overall health. Like the FACT-P, it can be
self-administered or used in an interview format within
11 to 12 min [14]. Functioning scales include physical
(ﬁve items), emotional (four items), cognitive (two
items), role (two items), and social (two items) func-
tioning as well as global health status (two items).
Symptom scales measure nausea and vomiting (two
items), fatigue (three items), and pain (two items), and
six single items assessing ﬁnancial impact and various
physical symptoms. Possible scores range from 0 to
100, with higher mean scores on the functional scales
representing better functioning and higher mean
scores on the symptom scales representing worse
symptomatology.
Methods
Study Sample and Data Collection
The study sample came from a multicenter, prospec-
tive observational study of patients with metastatic
HRPCA conducted between June 5, 2002 and January
8, 2004. Study centers were located in North America,
Europe, and Australia. Inclusion criteria were as
follows: 19 years or older; histologically documented
diagnosis of prostate adenocarcinoma (PCa) with
hormone-refractory status. Patients were excluded if
they were unable to comply with the requirements, had
received an investigational product 4 weeks before the
ﬁrst day of the study, or were eligible for and planned
to enter a study with another investigational product
at enrollment.
Patient preference-adjusted health status (measured
by EQ-5D) and HRQoL (measured by FACT-P and
EORTC QLQ-C30) were collected at enrollment and
follow-up visits at 3, 6, and 9 months after enrollment.
The HRQoL data from this study have been presented
previously [15]. Patient demographics and oncological
history/disease staging information were collected at
enrollment. The demographic information recorded
included patient country, race, age, height, and weight
as well as insurance status, educational level, marital
status, and distance between residence and treatment
center. Informed consent was required before patient
enrollment.
Model Selection
Three different regression methods were used to build
prediction models. First, ordinary least square (OLS)
regression was used to construct linear prediction
models of EQ-5D. Second, two additional regression
methods were included in the model selection to
address the potential ceiling and ﬂoor effects routinely
observed with preference-adjusted health status
responses: 1) OLS regression using only observations
with an EQ-5D summary score less than 1; and 2)
median regression. The median regression method esti-
mates coefﬁcients by minimizing the sum of the abso-
lute value of observed outcome variation from the
regression line [16,17]. Even though the median
regression model does not explicitly deal with censor-
ing, previous research showed that it is equivalent to
censored least absolute deviations regression when
censoring occurred in less than 50% of the study
sample [18].
Patient HRQoL and demographics were included in
the prediction models. To increase the usability of the
developed mapping algorithm, we only included the
most basic, and commonly collected, demographics.
The majority of the patients enrolled were white
(98%). Therefore, race was not included as a demo-
graphic effect in the models. To include HRQoL mea-
sures in the prediction model, for each of the
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regression methods identiﬁed above, four different sets
of explanatory variables were compared to select the
best model speciﬁcation:
1. FACT-P OVERALL score, EORTC QLQ-C30
component scores, demographics, and NO inter-
action terms between HRQoL measures and
demographic variables.
2. FACT-P OVERALL score, EORTC QLQ-C30
component scores, demographics, and WITH
interaction terms between HRQoL measures and
demographic variables.
3. FACT-P INDIVIDUAL COMPONENT scores,
EORTC QLQ-C30 component scores, demo-
graphics, and NO interaction terms between
HRQoL measures and demographic variables.
4. FACT-P INDIVIDUAL COMPONENT scores,
EORTC QLQ-C30 component scores, demo-
graphics, WITH interaction terms between
HRQoL measures and demographic variables.
The demographic variables included in the model
speciﬁcations were patient country, age, age-squared,
and body-mass index (BMI) computed from the
recorded patient height and weight. If the predicted
value of EQ-5D fell outside the deﬁned range of
[-0.594, 1.000], then it was truncated to the appro-
priate boundary value.
When assessing prediction model performance,
algorithm development data must be distinguished
from the data used for model performance assess-
ment. Because a prediction model usually performs
better with the data that were used in its develop-
ment, it is critical to evaluate how well the model
works with other data sets. This approach is generally
referred to as cross-validation. Following on previous
research, we estimated the cross-validation R2 as the
primary indicator of prediction model performance
[19–22]. Cross-validation sum of squared errors
(SSE), the absolute deviation of the predicted mean,
and the ﬁrst quartile, median, and third quartile of
the absolute deviation, were also estimated as second-
ary indicators of prediction model performance.
Selection of the model was based mainly on the
primary indicator. The secondary indicators were
used to further check the performance of the selected
model and as a benchmark when the model selection
is not obvious based solely on the primary indicator
(i.e., the cross-validation R2). To calculate the cross-
validation model performance indicators, the study
sample was ﬁrst divided into 10 equally sized groups.
Each group was used successively to test each model
and the remaining 90% of the sample were used to ﬁt
the prediction model. The resulting estimated predic-
tion model was then used to estimate the performance
of the original 10% of the sample. Finally, the esti-
mated error terms were pooled to estimate the overall
performance of the model.
Additional Tests and Reﬁnement of the Selected Model
The best-ﬁt model was further reﬁned to improve
performance and simplicity. The modiﬁed models
were compared with the original model using cross-
validation statistics and the ﬁnal model was selected
based primarily on the validation R2. F-tests were also
conducted for models with simpliﬁed speciﬁcations to
test whether the simpliﬁcations were reasonable. The
modiﬁed models included the following speciﬁcations:
1) excluding EORTC QLQ-C30; 2) using a more
coarsely grouped country variable (United States,
Canada, Australia, Europe); 3) excluding country
effect only; 4) excluding both country effect and BMI;
5) excluding BMI only; 6) adding second order
HRQoL terms (i.e., square and interaction terms); and
7) adding BMI squared.
Results
Study Sample Characteristics
The study enrolled 280 patients in seven countries:
Australia (n = 40), Canada (n = 48), France (n = 26),
Germany (n = 34), Italy (n = 52), the UK (n = 29), and
the United States (n = 51). Italy had the highest pro-
portion of patients (18.6%), whereas France had the
smallest (9.3%). The majority of the patients enrolled
were white (98%); therefore, race was not included as
a demographic effect in the models. The study sample
had an average age of 72.4 years (SD = 9.0) and an
average BMI of 72.4 (SD = 9.0).
As a result of the large number of patient dropouts
and deaths during the study, only the baseline EQ-5D
and quality of life data were used to develop the
mapping algorithm (prediction model). This approach
was taken to simplify the model and to avoid making
additional assumptions regarding missing values and
early patient dropout. Table 1 presents descriptive sta-
tistics of EQ-5D and HRQoL measures at the baseline
visit.
The average baseline EQ-5D is 0.64 (SD = 0.31),
with a median of 0.73 and a skewness of -1.53.
Model Selection
The three regression methods had four different speci-
ﬁcations each, for a total of 12 model speciﬁcations.
The cross-validation results for all prediction models
are presented in Table 2. The best-performing model is
the OLS model using the component scores of FACT-P
and no interaction terms. Its cross-validation R2
(0.582) is the highest and its cross-validation SSE
(0.920) is the lowest among all models. Compared
with other estimates, this model’s mean and median
absolute deviations (0.146 and 0.122, respectively) are
among the lowest values. When run on the full sample
instead of cross-validation samples, the model pro-
duced an R2 of 0.732. Therefore, it explains 58.2% of
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the observed EQ-5D variation in the validation sample
and 73.2% of the variation in the development sample.
The predicted EQ-5D values have a mean of 0.62
(SD = 0.27), compared with 0.64 (SD = 0.31) for the
observed EQ-5D values. The 25th, 50th, and 75th
percentiles of the predicted EQ-5D values are 0.46,
0.68, and 0.82, compared with 0.60, 0.73, and 0.80
for the observed EQ-5D values.
Additional Tests and Reﬁnement of the Selected Model
None of the simpliﬁed models with modiﬁed speciﬁca-
tions generated cross-validationR2 higher than its origi-
nal model. The results of testing other speciﬁcations are
presented in Table 3. The F-test results of various
restricted models indicated that all of the restrictions
signiﬁcantly decreased the ability of the prediction
model to explain the variation of the observed EQ-5D
values, with the exception of the model excluding only
BMI (P = 0.04). This simpliﬁed model has a cross-
validation R2 of 0.578, very close to that of the full
model. Therefore, researchers should use the original
prediction model whenever possible. Nevertheless,
when BMI is not collected, a simpliﬁed model can be
used without signiﬁcantly sacriﬁcing the prediction
power of the model.
A simpliﬁed model excluding EORTC QLQ-C30 as
an independent variable had a cross-validation R2 of
0.54, a cross-validation SSE of 1.02, a mean absolute
deviation of 0.15, and a median absolute deviation of
0.10. When run on the full sample, instead of the
cross-validation samples, the model produced an R2 of
0.62. This model can be used to predict HRPCA
patient EQ-5D when only FACT-P data are collected
for HRQoL. Therefore, it may be of particular interest
to researchers who only collect FACT-P from HRPCA
patients. The weights for the ﬁnal full linear prediction
model and the restricted model excluding EORTC
QLQ-C30 are presented in Table 4.
Table 1 Descriptive baseline statistics for health utility and
HRQoL variables
Variable N Mean SD
EQ-5D score 276 0.635 0.309
FACT-P variables
Physical well-being 279 20.9 5.5
Social well-being 276 21.0 4.7
Emotional well-being 279 17.2 4.6
Functional well-being 279 16.6 6.9
Total FACT-G 275 75.4 16.5
FACT-P prostate
Cancer subscore 280 29.8 7.8
Total FACT-P 275 105.1 22.5
EORTC variables
Global health 277 59.9 23.2
Physical functioning 278 68.8 25.7
Role functioning 279 65.8 32.9
Emotional functioning 278 73.6 22.8
Cognitive functioning 278 77.0 22.3
Social functioning 278 71.7 28.6
Fatigue 278 41.5 25.9
Nausea and vomiting 278 8.5 17.7
Pain 280 33.9 30.0
Dyspnea 278 22.3 28.7
Insomnia 278 27.2 30.7
Appetite loss 276 19.9 29.6
Constipation 278 23.0 29.3
Diarrhea 277 9.6 21.1
Financial difﬁculties 276 15.3 25.9
EORTC, European Organization for Research and Treatment of Cancer; FACT-G,
Functional Assessment of Cancer Therapy—General; FACT-P, Functional Assessment
of Cancer Therapy—Prostate; HRQoL, health-related quality of life.









Mean First quartile Median Third quartile
Simple OLS using all patients
Using the overall FACT-P score
Not including interaction terms 0.561 0.959 0.149 0.057 0.120 0.207
Including interaction terms 0.283 1.512 0.184 0.074 0.142 0.267
Using individual components of FACT-P
Not including interaction terms 0.582 0.920 0.146 0.052 0.122 0.214
Including interaction terms 0.259 1.531 0.182 0.061 0.134 0.258
OLS excluding patients with EQ-5D
equal to 1 (ceiling effect)
Using the overall FACT-P score
Not including interaction terms 0.538 0.984 0.154 0.066 0.124 0.217
Including interaction terms 0.159 1.795 0.195 0.063 0.158 0.275
Using individual components of FACT-P
Not including interaction terms 0.561 0.946 0.150 0.054 0.124 0.214
Including interaction terms 0.129 1.860 0.197 0.064 0.146 0.269
Median regression using all patients
Using the overall FACT-P score
Not including interaction terms 0.573 1.001 0.134 0.039 0.103 0.180
Including interaction terms 0.121 1.903 0.152 0.018 0.109 0.232
Using individual components of FACT-P
Not including interaction terms 0.555 1.038 0.136 0.046 0.102 0.188
Including interaction terms 0.220 1.626 0.132 0.009 0.081 0.190
FACT-P, Functional Assessment of Cancer Therapy—Prostate; OLS, ordinary least square.
Mapping Prostate Cancer HRQoL to EQ-5D 411
Discussion
The prediction model of patient preference-adjusted
health status constructed and tested in this study had
good predictive validity for metastatic HRPCA. It pre-
dicted 58.2% of the observed EQ-5D variation in the
cross-validation sample, and 73.2% of the variation in
the development sample. In comparison, Nichol et al.
[6] predicted 50% of the observed variance in HUI
scores using SF-36 scores, and Sengupta et al. [7] pre-
dicted 47% of the observed variance in HUI using
SF-12 scores. Gray et al. [10] compared the perfor-
mance of their mapping algorithm of SF-12 to EQ-5D
with the one developed by Franks et al. [9]. Gray’s
mapping algorithm had a mean absolute deviation of
0.15 for patients with long-standing illness, whereas
Frank’s mapping algorithm had a mean absolute
deviation of 0.14 for the same study sample. Our study
sample had a mean absolute deviation of 0.146, com-
parable to the other two models (Table 5).
The inclusion criteria of the study are rather broad
and future clinical studies will most likely apply similar
criteria. Therefore, the study participants are likely
to be good representatives of potential population of
individuals who might participate in future HRPCA
clinical trials.
In the process of selecting models, we found that
overall, models with interaction terms of HRQoL and
demographic variables performed worse than those
without interaction terms. This is likely due to overﬁt-
ting of the model when interaction terms were
included, which made the prediction model ﬁt “too
well” for the development sample. This is usually
caused by the inclusion of variables that are useful
predictors of outcome variables in development data,
Table 3 Model testing and reﬁnement














Original model 0.582 0.920 0.146 0.052 0.122 0.214
Excluding EORTC 0.535 1.023 0.146 0.050 0.103 0.209 <0.01
Grouped country effects (USA, Canada,Australia, Europe) 0.567 0.953 0.145 0.049 0.113 0.199 <0.01
Excluding country effects 0.560 0.967 0.145 0.053 0.118 0.207 <0.01
Excluding country effects, body-mass index 0.561 0.966 0.144 0.051 0.114 0.198 <0.01
Excluding body-mass index 0.578 0.927 0.145 0.051 0.113 0.207 0.04
Full model plus second order HRQoL terms 0.568 0.951 0.143 0.046 0.110 0.212 —
Full model plus the square of BMI 0.580 0.924 0.146 0.050 0.123 0.212 —
EORTC, European Organization for Research and Treatment of Cancer; health-related quality of life.
Table 4 Linear weights of selected prediction models
Variable




Physical well-being 0.013 0.027
Social well-being -0.001 -0.003
Emotional well-being 0.007 0.009
Functional well-being -0.003 0.002
FACT-P subscale 0.003 0.009
Square of FACT-P — —
EORTC QLQ-C30*
Global health 0.000 —
Physical functioning 0.003 —
Role functioning -0.002 —
Emotional functioning 0.002 —
Cognitive functioning 0.001 —
Social functioning 0.001 —
Fatigue 0.000 —




Appetite loss 0.000 —
Constipation -0.001 —
Diarrhea 0.000 —
Financial difﬁculties 0.000 —
Demographics
Patient age 0.007 0.009
Square of patient age 0.000 0.000








*All dimensions of EORTC range from 0 to 100; 100 represents the best possible
outcome for Global Health, Physical Functioning, Role Functioning, Emotional Func-
tioning, Cognitive Functioning, and Social Functioning, and the worse possible
outcome for all other dimensions.
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire; FACT-P, Functional Assessment of Cancer
Therapy—Prostate.
Table 5 Sensitivity and speciﬁcity
Percentile
Final full model Excluding EORTC
Sensitivity Speciﬁcity Sensitivity Speciﬁcity
10 0.548 0.904 0.323 0.960
20 0.852 0.765 0.796 0.836
30 0.836 0.700 0.904 0.725
40 0.853 0.655 0.908 0.708
50 0.890 0.674 0.934 0.688
60 0.840 0.703 0.864 0.729
70 0.863 0.644 0.879 0.611
80 0.829 0.638 0.847 0.655
90 0.992 0.184 0.988 0.132
EORTC, European Organization for Research and Treatment of Cancer.
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but do not generalize well to other data [23]. At base-
line, 13.8% of the study sample had the highest pos-
sible EQ-5D score (1.000) and only 0.7% had the
lowest possible score (-0.594). Therefore, ﬂoor effect
was not considered in the study.
For the study of patient HRQoL and preference-
adjusted health status, comparison of results across
different studies and different diseases is important. As
a generic health status measure, EQ-5D has been
widely used in research of different diseases and con-
ditions. Therefore, when the actual measure of EQ-5D
is not available, the ability to “translate” cancer and
prostate cancer-speciﬁc HRQoL measures to EQ-5D
makes it possible to compare outcomes from HRPCA
patients with those from patients with different kinds
of cancer or with other diseases. Furthermore, linking
HRPCA patient HRQoL to a single-dimension generic
preference-adjusted health status measure also enables
the calculation of quality of life-adjusted life-year and
the analysis of cost-utility. With the advance of cancer
treatment, prolonged patient lives, awareness of
patient quality of life, and constrained health-care
budgets, the ability to estimate cost-utility of interven-
tions and to compare them across different interven-
tions and diseases is becoming ever more important for
decision-makers to optimize medical resource alloca-
tion. Of course, a translated measure of EQ-5D should
be considered a ﬁx, rather than a substitution, for
actual health status information. We recommend the
collection of EQ-5D in future prospective studies of
HRPCA patient when resources allow.
Population average EQ-5D varies by demographics
characteristics, economic status, social class, and popu-
lation base across different countries [11,24]. Our ﬁnal
mapping algorithm in Table 4 showed that HRPCA
patients in different countries have different baseline
EQ-5D when the UK preference weight is used.
In this study, we decided a priori to use cross-
validation R2 as the primary measure of model predic-
tive validity following previous research [19–22].
Because OLS seeks to minimize the residual sum of
squares and median regression seeks to minimize the
absolute deviation, normally OLS will outperform
median regression using cross-validation R-squared as
the selection criterion. The purpose of applying
median regression as an alternative model is that it
may outperform OLS when there is ceiling effect.
Judging from cross-validation R2, OLS is still a better
prediction model compared with median regression at
the presence of current level of ceiling effect. Never-
theless, as Table 2 showed, the median regression
model outperformed OLS on measures of absolute
deviation. Given that the unconditional distribution of
EQ-5D is skewed, median of absolute deviation could
be the preferred measure of predictive validity. In that
case, the median model will outperform OLS accord-
ing to results in Table 2.
A limitation of using regression methods to develop
a prediction model is that the prediction precision may
be arbitrarily increased because of the fact that pre-
dicted values always have the same average as the
observed values in the model development sample. A
second limitation of the study is the lack of racial
diversity of the study sample. Future studies with
larger samples and a more diversiﬁed racial proﬁle may
be conducted to evaluate the prediction model devel-
oped in this study. In addition, the mapping algorithm
was developed based on the UK preference weight of
EQ-5D. Future study may be conducted to develop the
mapping algorithm based on the recently developed US
preference weight of EQ-5D to yields preferences that
are more culturally relevant to the US population.
Another limitation of the study is that it did not
address how well the predicted EQ-5D measure inter-
vention effect compared with the observed EQ-5D.
Future studies with longitudinal measures of EQ-5D
should be conducted to assess the mapping algorithm’s
ability to accurately assess impacts of interventions.
Source of ﬁnancial support: This research was funded by
Abbott Laboratories.
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